Imlifidase Utilization in Glanzmann Thrombasthenia with Anti-GPIIb/IIIa and Anti-HLA Alloimmunization and Severe Platelet Refractoriness following Hematopoietic Stem Cell Transplant.
Mohammad AlNajjar,
Ryan Rochat,
Amanda Grimes
et al.
Abstract:Glanzmann Thrombasthenia (GT) is an inherited bleeding disorder of poor
platelet function secondary to a defect in platelet membrane
glycoprotein IIb/IIIa (GPIIb/IIIa). Patients with GT may develop
anti-platelet antibodies including anti-GPIIb/IIIa which can lead to
severe refractory thrombocytopenia and life-threatening bleeding,
management of which is challenging. We report successful use of
imlifidase, a novel IgG protease enzyme, as part of a multimodal
approach for management of severe platelet refractori… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.